Share price · LGND
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when LGND's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 12 Oct 2026+3.1%
Nothing announced by LGND that day or the session before.
- 23 Jun 2026+6.6%
- 7 May 2026-9.6%
- 27 Apr 2026+4.5%
- 14 Apr 2026+8.9%
- 11 Mar 2026+4.2%
Nothing announced by LGND that day or the session before.
- 13 Jan 2026-8.7%
Nothing announced by LGND that day or the session before.
Share of unusual movement by asset
For each asset, the share of LGND's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
VK2809events and moves
| 2 | shown from 8 days |
berdazimer (Zelsuvmi)events and moves
| 1 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 0% |
| Other company news (earnings, financing, releases naming no asset) | — | 35% |
| Sessions with no dated event | — | 65% |
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
berdazimer(Zelsuvmi) | Approved | Nitric oxide releaseSmall molecule | Molluscum Contagiosum |
| Phase 2 | Thyroid hormone receptor-betaSmall molecule | MASH / NASH |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (18)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $79M | $2.8M | $103M+ $391M short-term inv. | $28M-$28M operating cash flow | report ↗ |
View 17 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $64M | $15M | $1.0B+ $351M short-term inv. | —$24M operating cash flow | report ↗ |
| 2026-Q1 | $52M | $2.1M | $115M+ $664M short-term inv. | $13M$49M operating cash flow | report ↗ |
| 2025-Q3 | $115M | $21M | $139M+ $525M short-term inv. | —$13M operating cash flow | report ↗ |
| 2025-Q2 | $48M | $6.6M | $68M+ $177M short-term inv. | —$16M operating cash flow | report ↗ |
| 2025-Q1 | $45M | $50M | $48M+ $161M short-term inv. | $42M-$25M operating cash flow | report ↗ |
| 2024-Q3 | $52M | $5.7M | $64M+ $156M short-term inv. | $7.2M$37M operating cash flow | report ↗ |
| 2024-Q2 | $42M | $5.3M | $18M+ $209M short-term inv. | $52M$13M operating cash flow | report ↗ |
| 2024-Q1 | $31M | $6.0M | $50M+ $261M short-term inv. | —$19M operating cash flow | report ↗ |
| 2023-Q3 | $33M | $5.5M | $20M+ $171M short-term inv. | $10M$7.7M operating cash flow | report ↗ |
| 2023-Q2 | $26M | $6.8M | $28M+ $191M short-term inv. | —-$0.1M operating cash flow | report ↗ |
| 2023-Q1 | $44M | $6.7M | $89M+ $194M short-term inv. | —$34M operating cash flow | report ↗ |
| 2022-Q4 | $50M | $9.2M | $45M+ $167M short-term inv. | $17M$53M operating cash flow | report ↗ |
| 2022-Q3 | $66M | $22M | $4.1M+ $117M short-term inv. | —$20M operating cash flow | report ↗ |
| 2022-Q2 | $57M | $19M | $5.3M+ $143M short-term inv. | $0.9M$12M operating cash flow | report ↗ |
| 2022-Q1 | $46M | $20M | $15M+ $189M short-term inv. | $15M$52M operating cash flow | report ↗ |
| 2021-Q4 | $56M | $8.2M | $20M+ $322M short-term inv. | $5.4M$28M operating cash flow | report ↗ |
| 2021-Q3 | $65M | $17M | $23M+ $300M short-term inv. | —$20M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $268M | $81M | $175M+ $559M short-term inv. | —$49M operating cash flow | report ↗ |
Ligand Pharmaceuticals reported full-year 2025 revenue of $268.09M, up 60.4% YoY, with R&D spend of $81.18M, up 278.8% YoY. Cash and equivalents stood at $174.93M, and GAAP net income was $124.45M.
Management reiterated 2026 guidance of $245–$285M in total revenue and adjusted EPS of $8.00–$9.00. Key disclosed developments included positive Phase 3 results for Palvella’s Qtorin rapamycin, regulatory progress for Ohtuvayre, Filspari, and Tzield, UroGen’s discontinuation of UGN-301, and new royalty rights related to Xepi and lasofoxifene.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $167M | $21M | $72M+ $184M short-term inv. | $1.0M$97M operating cash flow | report ↗ |
| 2023-FY | $131M | $25M | $23M+ $147M short-term inv. | —$50M operating cash flow | report ↗ |
| 2022-FY | $196M | $36M | $45M+ $167M short-term inv. | $8.3M$138M operating cash flow | report ↗ |
| 2021-FY | $277M | $69M | $20M+ $322M short-term inv. | —$79M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 151 sales ($36.5M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-12 | Zimmermann Martine · director | Open-market sale | 2,000 | $318.17 | $636K | Form 4 |
| 2026-11-12 | KOZARICH JOHN W · director | Open-market sale | 500 | $325.00 | $163K | Form 4 |
| 2026-11-10 | Aryeh Jason · director | Open-market sale | 500 | $319.99 | $160K | Form 4 |
| 2026-11-10 | Aryeh Jason · director | Open-market sale | 844 | $320.00 | $270K | Form 4 |
| 2026-11-10 | Aryeh Jason · director | Open-market sale | 646 | $320.00 | $207K | Form 4 |
| 2026-11-10 | Aryeh Jason · director | Open-market sale | 10 | $320.02 | $3K | Form 4 |
| 2026-11-10 | Aryeh Jason · director | Open-market sale | 500 | $320.10 | $160K | Form 4 |
| 2026-11-10 | Aryeh Jason · director | Open-market sale | 500 | $320.20 | $160K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 352 reporting institutions held 20.8M shares ($4.1B, 103.8% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 2,961,923 | $591.3M |
| 2 | VANGUARD PORTFOLIO MANAGEMENT LLC | 1,100,267 | $219.7M |
| 3 | JANUS HENDERSON GROUP PLC | 1,009,891 | $201.6M |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 848,089 | $169.3M |
| 5 | Invesco Ltd. | 823,604 | $164.4M |
| 6 | STATE STREET CORP | 778,856 | $155.5M |
| 7 | FMR LLC | 596,127 | $119.0M |
| 8 | NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 573,312 | $114.5M |
| 9 | FRANKLIN RESOURCES INC | 573,177 | $114.4M |
| 10 | Chicago Capital, LLC | 561,675 | $112.1M |
| 11 | GEODE CAPITAL MANAGEMENT, LLC | 558,934 | $111.6M |
| 12 | CONGRESS ASSET MANAGEMENT CO | 504,637 | $100.8M |
| 13 | Stephens Investment Management Group LLC | 494,670 | $98.8M |
| 14 | DIMENSIONAL FUND ADVISORS LP | 425,230 | $84.9M |
| 15 | MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 411,543 | $82.2M |